Part 1 TPST-1120 + Part 2 TPST-1120 + nivolumab + Part 3 TPST-1120 + Part 4 TPST-1120 + nivolumab
Phase 1CompletedDevelopment Stage
Hepatocellular Carcinoma
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Mar 20, 2019 → Sep 7, 2022
About Part 1 TPST-1120 + Part 2 TPST-1120 + nivolumab + Part 3 TPST-1120 + Part 4 TPST-1120 + nivolumab
Part 1 TPST-1120 + Part 2 TPST-1120 + nivolumab + Part 3 TPST-1120 + Part 4 TPST-1120 + nivolumab is a phase 1 stage product being developed by Tempest Therapeutics for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03829436. Target conditions include Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03829436 | Phase 1 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma